Article Information
- Received January 10, 2012
- Revision received May 1, 2012
- Accepted May 12, 2012
- First published July 4, 2012.
- Version of record published July 4, 2012.
Author Information
- Teodoro Bottiglieri1,
- Erland Arning1,
- Brandi Wasek1,
- Viyada Nunbhakdi-Craig2,
- Jean-Marie Sontag3, and
- Estelle Sontag3
- 1Institute of Metabolic Disease, Baylor Research Institute, Dallas, Texas 75226,
- 2Department of Pathology, University of Texas, Southwestern Medical Center, Dallas, Texas 75390, and
- 3School of Biomedical Sciences and Pharmacy, Faculty of Health, University of Newcastle, Callaghan, New South Wales 2308 Australia
Author contributions
Author contributions: T.B. and E.S. designed research; T.B., E.A., B.W., V.N.-C., J.-M.S., and E.S. performed research; T.B., E.A., J.-M.S., and E.S. analyzed data; T.B. and E.S. wrote the paper.
Disclosures
- Received January 10, 2012.
- Revision received May 1, 2012.
- Accepted May 12, 2012.
This work was supported by National Institutes of Health Grant AG18883 (E.S.); startup funds from the University of Newcastle, Australia (E.S.); and a project grant from the National Health and Medical Research Council of Australia (E.S. and J.-M.S.).We thank Dr. Peter Davies (Albert Einstein College of Medicine, NY) for the gift of PHF-1 antibodies and Dr. Philip Dickson (University of Newcastle, Australia) for the gift of anti-TH antibodies.
T.B. reports having been the chairman of the Advisory Board for Methylation Sciences Inc., holding stock options in Methylation Sciences Inc., being a scientific consultant to Pamlab LLC, and having received research funding from Pamlab LLC, which is a distributor of B vitamins as a medical food.
- Correspondence should be addressed to Dr. Teodoro Bottiglieri, Institute of Metabolic Disease, Baylor Research Institute, 3812 Elm Street, Dallas, Texas 75226. teodorob{at}baylorhealth.edu
Online Impact